Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Concordia’s Photodynamic Therapy Laser Receives Premarket Ap
View:
Post by wordless on Jul 19, 2016 10:34am

Concordia’s Photodynamic Therapy Laser Receives Premarket Ap

 

  • Concordia’s Photodynamic Therapy Laser Receives Premarket Approval
OAKVILLE, Ontario, July 19, 2016 — Concordia International Corp. said that the U.S. Food and Drug Administration has approved the Company's premarket approval application for its Photofrin 630 PDT (photodynamic therapy) Laser. 

PDT with Photofrin is a light-based cancer treatment that combines the photosensitizing drug Photofrin (porfimer sodium) with a specific wavelength of laser light to attack cancer cells. 

Concordia said the newly approved laser — designed for use with Photofrin to treat esophageal cancer, Barrett's Esophagus and non-small cell lung cancer — has been re-engineered with new controls and peripheral systems, while maintaining the same specifications with minimal changes to the treatment procedures. 

The Company is also evaluating Photofrin as a potential treatment for cholangiocarcinoma, or bile duct cancer, which is a rare disease affecting approximately 2,000 to 3,000 patients annually in the U.S.
 
Comment by LatticeInExile on Jul 19, 2016 12:03pm
This post has been removed in accordance with Community Policy
Comment by GoldBug024 on Jul 19, 2016 12:39pm
Sounds like an innovation to me. Innovate is to make changes to something established, especially by introducing new methods, ideas or products. Wish you were innovative Lattice but it's the same old song and dance LOLLL csn we put a new switch on you to turn you off?
Comment by CdnNewby on Jul 19, 2016 1:48pm
Lattice in Exile/ Yolanda? ,   I am interested in how much you know about the changes Concordia has made to their laser.  Please explain to us how you  truly know that  Concordia's  "reengineered with new controls and peripheral systems:   does not involve innovative changes.  I don't know that it does, but please prove to us that it doesn't by ...more  
Comment by LatticeInExile on Jul 19, 2016 2:52pm
This post has been removed in accordance with Community Policy
Comment by GoldBug024 on Jul 19, 2016 2:56pm
Poor Yolanda....I guess egg man won't pay the bills if he can't cover LOL
Comment by GoldBug024 on Jul 19, 2016 3:21pm
Goldbug, the only bag she will be holding is the one over her head when Marc doesn't giver her her money... Honey
Comment by LatticeInExile on Jul 19, 2016 3:29pm
This post has been removed in accordance with Community Policy
Comment by LatticeInExile on Jul 22, 2016 12:52pm
This post has been removed in accordance with Community Policy
Comment by LatticeInExile on Jul 23, 2016 3:31pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse